Skip to main content
SpringerLink
Log in

PSA Dynamics

  • Chapter
  • First Online:
Prostate Cancer Diagnosis

Part of the book series: Current Clinical Urology ((CCU))

  • 1537 Accesses

Abstract

Prostate-specific antigen (PSA) is widely used today for the diagnosis and management of men with prostate cancer. It is well known that PSA screening has led to a major stage migration, with most prostate cancers now diagnosed at a localized, curable stage (National Cancer Institute Surveillance Research Program SEER*Stat software, 6.2.4 edn. Available at: http://www.seer.cancer.gov/seerstat). Epidemiologic studies have also shown that prostate cancer mortality rates are lowest in areas where the rates of distant-stage disease are lowest, and distant-stage disease is lowest in areas with the highest PSA utilization (Jemal et al. Cancer Epidemiol Biomarkers Prev 14(3):590–5, 2005). Finally, randomized trials of PSA screening have recently been reported. The European Randomized Study of Screening for Prostate Cancer (ERSPC) and the Goteborg population-based screening trial (including a subset of Swedish ERSPC participants) reported a 21 % and 44 % relative reduction in prostate cancer mortality with screening at 11 and 14 years, respectively (Schroder et al. N Engl J Med Hugosson et al. Lancet Oncol 11(8):725–32, 2010). The US Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial reported no difference in mortality with screening in the overall results (Andriole et al. JNCI 2012; 104: 125-32).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. National Cancer Institute Surveillance Research Program SEER*Stat software, 6.2.4 edn. Available at: http://www.seer.cancer.gov/seerstat.

  2. Jemal A, Ward E, Wu X, et al. Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol Biomarkers Prev. 2005;14(3):590–5.

    Article  PubMed  Google Scholar 

  3. Schröder FH, Hugosson J, Roobol MJ, et al. ERSPC Investigators. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012; 366(11):981–90. Erratum in: N Engl J Med. 2012;366(22):2137. PMID: 22417251.

    Article  PubMed  Google Scholar 

  4. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11(8):725–32.

    Article  PubMed  Google Scholar 

  5. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. PLCO Project Team. J Natl Cancer Inst. 2012;104(2):125–32. Epub 2012 Jan 6. PMID: 22228146.

    Article  PubMed  CAS  Google Scholar 

  6. Ercole CJ, Lange PH, Mathisen M, et al. Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol. 1987;138(5):1181–4.

    PubMed  CAS  Google Scholar 

  7. Jansen FH, Roobol M, Bangma CH, van Schaik RH. Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection. Clin Chem. 2008;54(12):1999–2006.

    Article  PubMed  CAS  Google Scholar 

  8. Loeb S, Carter HB, Walsh PC, et al. Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level. J Urol. 2009;182(1):101–4. Discussion 105.

    Article  PubMed  CAS  Google Scholar 

  9. D’Amico AV, Roehrborn CG. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol. 2007;8(1):21–5.

    Article  PubMed  Google Scholar 

  10. Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ. The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst. 2008;100(21):1511–8.

    Article  PubMed  CAS  Google Scholar 

  11. Banez LL, Hamilton RJ, Partin AW, et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 2007; 298(19):2275–80.

    Article  PubMed  Google Scholar 

  12. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992; 267(16):2215–20.

    Article  PubMed  CAS  Google Scholar 

  13. Carter HB, Morrell CH, Pearson JD, et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res. 1992;52(12):3323–8.

    PubMed  CAS  Google Scholar 

  14. Carter HB, Pearson JD, Waclawiw Z, et al. Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology. 1995;45(4):591–6.

    Article  PubMed  CAS  Google Scholar 

  15. D’Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351(2):125–35.

    Article  PubMed  Google Scholar 

  16. Yu X, Han M, Loeb S, et al. Comparison of methods for calculating prostate specific antigen velocity. J Urol. 2006;176(6 Pt 1):2427–31. Discussion 2431.

    Article  PubMed  Google Scholar 

  17. Riehmann M, Rhodes PR, Cook TD, Grose GS, Bruskewitz RC. Analysis of variation in prostate-specific antigen values. Urology. 1993;42(4):390–7.

    Article  PubMed  CAS  Google Scholar 

  18. Prestigiacomo AF, Stamey TA. Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers. J Urol. 1996;155(6):1977–80.

    Article  PubMed  CAS  Google Scholar 

  19. Roehrborn CG, Pickens GJ, Carmody 3rd T. Variability of repeated serum prostate-specific antigen (PSA) measurements within less than 90 days in a well-defined patient population. Urology. 1996;47(1): 59–66.

    Article  PubMed  CAS  Google Scholar 

  20. Eastham JA, Riedel E, Scardino PT, et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA. 2003;289(20):2695–700.

    Article  PubMed  CAS  Google Scholar 

  21. Smith DS, Catalona WJ. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol. 1994;152(4):1163–7.

    PubMed  CAS  Google Scholar 

  22. Kadmon D, Weinberg AD, Williams RH, et al. Pitfalls in interpreting prostate specific antigen velocity. J Urol. 1996;155(5):1655–7.

    Article  PubMed  CAS  Google Scholar 

  23. Lujan M, Paez A, Sanchez E, et al. Prostate specific antigen variation in patients without clinically evident prostate cancer. J Urol. 1999;162(4):1311–3.

    Article  PubMed  CAS  Google Scholar 

  24. Raaijmakers R, Wildhagen MF, Ito K, et al. Prostate-specific antigen change in the European randomized study of screening for prostate cancer, section Rotterdam. Urology. 2004;63(2):316–20.

    Article  PubMed  Google Scholar 

  25. Berger AP, Deibl M, Steiner H, et al. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. Prostate. 2005;64(3):240–5.

    Article  PubMed  Google Scholar 

  26. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993;270(7):860–4.

    Article  PubMed  CAS  Google Scholar 

  27. Fang J, Metter EJ, Landis P, Carter HB. PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml. Urology. 2002;59(6):889–93. Discussion 893–4.

    Article  PubMed  Google Scholar 

  28. Roobol MJ, Kranse R, de Koning HJ, Schroder FH. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Urology. 2004;63(2):309–13. Discussion 313–5.

    Article  PubMed  CAS  Google Scholar 

  29. Loeb S, Roehl KA, Nadler RB, Yu X, Catalona WJ. Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml. J Urol. 2007;178(6):2348–52. Discussion 2352–3.

    Article  PubMed  CAS  Google Scholar 

  30. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. http://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf (2012). Accessed 4 Sep 2012.

  31. Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst. 2011;103(6):462–9.

    Article  PubMed  Google Scholar 

  32. Loeb S, Roehl KA, Helfand BT, Kan D, Catalona WJ. Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection? J Urol. 2010;183(1):112–6. PMID: 19913814.

    Google Scholar 

  33. Loeb S, Carter HB, Schaeffer EM, et al. Distribution of PSA velocity by total PSA levels: data from the Baltimore Longitudinal Study of Aging. Urology. 2011;77(1):143–7.

    Article  PubMed  Google Scholar 

  34. Yu X, Loeb S, Roehl KA, Han M, Catalona WJ. The association between total prostate specific antigen concentration and prostate specific antigen velocity. J Urol. 2007;177(4):1298–302. Discussion 1301–2.

    Article  PubMed  Google Scholar 

  35. Loeb S, Roehl KA, Catalona WJ, Nadler RB. Is the utility of prostate-specific antigen velocity for prostate cancer detection affected by age? BJU Int. 2008;101(7):817–21.

    Article  PubMed  CAS  Google Scholar 

  36. Eggener SE, Yossepowitch O, Roehl KA, et al. Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program. Urology. 2008;71(6):1016–9.

    Article  PubMed  Google Scholar 

  37. Etzioni RD, Howlader N, Shaw PA, et al. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol. 2005;174(3):877–81.

    Article  PubMed  CAS  Google Scholar 

  38. Loeb S, Sutherland DE, D’Amico AV, Roehl KA, Catalona WJ. PSA velocity is associated with Gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness. Urology. 2008;72(5):1116–20. Discussion 1120.

    Article  PubMed  Google Scholar 

  39. D’Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005;294(4):440–7.

    Article  PubMed  Google Scholar 

  40. Sengupta S, Myers RP, Slezak JM, et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol. 2005;174(6): 2191–6.

    Article  PubMed  Google Scholar 

  41. Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst. 2006;98(21):1521–7.

    Article  PubMed  Google Scholar 

  42. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol. 2005;23(32):8165–9.

    Article  PubMed  Google Scholar 

  43. Ross AE, Loeb S, Landis P, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol. 2010;28(17):2810–6.

    Article  PubMed  CAS  Google Scholar 

  44. Loeb S, Kettermann A, Ferrucci L, et al. PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. Eur Urol. 2008;54(5):1073–80.

    Article  PubMed  Google Scholar 

  45. Vickers AJ, Savage C, O’Brien MF, Lilja H. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol. 2009;27(3):398–403.

    Article  PubMed  Google Scholar 

  46. Ward JF, Moul JW. Treating the biochemical recurrence of prostate cancer after definitive primary therapy. Clin Prostate Cancer. 2005;4(1):38–44.

    PubMed  Google Scholar 

  47. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation ­following radical prostatectomy. JAMA. 1999;281(17):1591–7.

    Article  PubMed  CAS  Google Scholar 

  48. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol. 2003;170(5): 1872–6.

    Article  PubMed  Google Scholar 

  49. D’Amico AV, Moul JW, Carroll PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95(18):1376–83.

    Article  PubMed  Google Scholar 

  50. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433–9.

    Article  PubMed  CAS  Google Scholar 

  51. Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291(11):1325–32.

    Article  PubMed  CAS  Google Scholar 

  52. D’Amico AV, Chen MH, Roehl KA, Catalona WJ. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol. 2005;23(22):4975–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, New York University, New York, NY, USA

    Stacy Loeb M.D.

  2. Department of Urology, Marburg 403, Johns Hopkins School of Medicine, 600 N Wolfe Street, Baltimore, MD, 21287, USA

    H. Ballentine Carter M.D.

Authors
  1. Stacy Loeb M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Ballentine Carter M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Ballentine Carter M.D. .

Editor information

Editors and Affiliations

  1. Cleveland Clinic, Cleveland Clinic Lerner College of Medic, Department of Regional Urology, at Case Western Reserve, Cleveland, 44195, Ohio, USA

    J. Stephen Jones

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Loeb, S., Carter, H.B. (2013). PSA Dynamics. In: Jones, J. (eds) Prostate Cancer Diagnosis. Current Clinical Urology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-188-2_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-188-2_4

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-187-5

  • Online ISBN: 978-1-62703-188-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation